EMEKLINDA

This brand name is authorized in Nigeria.

Active ingredients

The drug EMEKLINDA contains one active pharmaceutical ingredient (API):

1	Clindamycin UNII T20OQ1YN1W - CLINDAMYCIN HYDROCHLORIDE
	Clindamycin is a lincosamide antibiotic with a primarily bacteriostatic action against Gram-positive aerobes and a wide range of anaerobic bacteria. Lincosamides such as clindamycin bind to the 50S subunit of the bacterial ribosome and inhibit the early stages of protein synthesis.
	Read more about Clindamycin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
C4-0454	Capsule	EMEKLINDA 300 CAPSULES CAP 300 mg	EMEKLINDA 300 CAPSULES EMEKLINDA CLINDAMYCIN HYDROCHLORIDE BP EQ. TO CLINDAMYCIN 300MG POM CAPSULES 1 X 10 ANTIBIOTIC EMEK-JIORS PHARMACEUTICAL LTD NO. 7A, NIGER STREET SABON GARI, KANO STATE KWALITY PHARMACEUTICALS LTD VILLAGE NAG KALAN, MAJITHA ROAD, AMRISTAR, PINJAB- INDIA GMP-RBC LR- SATIS; FEES- PAID; NP: NA 15/10/2018 R R R C4-0454	30/01/2020
C4-0455	Capsule	EMEKLINDA 150 CAPSULES CAP 150 mg 1 X 10	EMEKLINDA 150 CAPSULES EMEKLINDA CLINDAMYCIN HYDROCHLORIDE BP EQ. TO CLINDAMYCIN 150MG POM CAPSULES 1 X 10 ANTIBIOTIC EMEK-JIORS PHARMACEUTICAL LTD NO. 7A, NIGER STREET SABON GARI, KANO STATE KWALITY PHARMACEUTICALS LTD VILLAGE NAG KALAN, MAJITHA ROAD, AMRISTAR, PINJAB- INDIA GMP-RBC LR- SATIS; FEES- PAID; NP: NA 15/10/2018 R R R C4-0455	30/01/2020

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01FF01	Clindamycin	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01F Macrolides, lincosamides and streptogramins → J01FF Lincosamides
Discover more medicines within J01FF01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	C4-0454, C4-0455